Tiffanie McDowell

Partner | She/Her/Hers

Overview

Tiffanie McDowell is a partner in Crowell & Moring’s Orange County office, where she practices in the firm’s Antitrust and Competition and Health Care groups. Tiffanie has deep experience in pharmaceutical drug pricing and issues that impact access to pharmaceutical drugs.    

Tiffanie represents health care clients in high stakes litigation and investigations involving pharmaceutical antitrust issues, vertical integration, drug pricing and reimbursement issues, and distribution and rebating arrangements. She also provides strategic counseling and representation concerning the 340B Drug Pricing Program, pharmacy benefit manager contracting, specialty pharmacy arrangements, and the evolving framework of state and federal laws governing pharmacy benefit managers and drug pricing and reimbursement obligations. Tiffanie brings a comprehensive understanding of the pharmaceutical supply chain to help clients resolve complex disputes, navigate regulatory requirements, and structure complex business arrangements. 

From 2017 to 2018, Tiffanie served as a judicial law clerk to the Honorable John F. Walter of the U. S. District Court for the Central District of California. Before joining Judge Walter’s chambers, Tiffanie was a floating law clerk to the Honorable Dale S. Fischer in the Central District

Career & Education

    • University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
    • University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
    • University of Missouri, B.S., cum laude, political science, 2006
    • University of Missouri, B.A., cum laude, international studies, 2006
    • University of Missouri, B.B.A., cum laude, international business, 2006
    • University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
    • University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
    • University of Missouri, B.S., cum laude, political science, 2006
    • University of Missouri, B.A., cum laude, international studies, 2006
    • University of Missouri, B.B.A., cum laude, international business, 2006
    • California
    • California

Tiffanie's Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...

Tiffanie's Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...